(LO-NYSE) SUMMARY. Risk Level *

Size: px
Start display at page:

Download "(LO-NYSE) SUMMARY. Risk Level *"

Transcription

1 February 12, 2015 Lorillard Inc. (LO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Outperform Date of Last Change 05/22/2012 Current Price (02/11/15) $67.55 Target Price $ Week High $ Week Low $47.31 One-Year Return (%) Beta 0.36 Average Daily Volume (sh) 2,179,247 Shares Outstanding (mil) 360 Market Capitalization ($mil) $24,318 Short Interest Ratio (days) 2.71 Institutional Ownership (%) 89 Insider Ownership (%) 0 SUMMARY Lorillard beat the Zacks Consensus Estimate on both earnings and revenues in the fourth quarter Earnings of $0.93 per share exceeded the prior-year earnings by 13.4% driven by higher cigarette sales and lower share count owing to share buyback activity. Sales increased 1.4% from the prior year quarter, driven by an increase in net sales of cigarettes owing to higher pricing, strong brands and growing market share, despite decline in cigarette shipment volumes. We also remain concerned about the recent decline in net sales of electronic cigarettes as a result of lower unit volume. Greater competition from rivals such as Altria Group and Reynolds American is also impacting sales of blu ecigs. Nevertheless, the recent news of shareholders approval for the company s merger with Reynolds American is encouraging. The companies expect the merger to complete in the first half of Risk Level * Low, Type of Stock N/A Industry Tobacco Zacks Industry Rank * 171 out of 267 ZACKS CONSENSUS ESTIMATES Revenue Estimates (In millions of $) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) Annual Cash Dividend $2.46 Dividend Yield (%) Yr. Historical Growth Rates Sales (%) 6.0 Earnings Per Share (%) 11.5 Dividend (%) 14.0 using TTM EPS 20.1 using 2015 Estimate 18.3 using 2016 Estimate ,122 A 1,288 A 1,827 A 1,253 A 6,950 A ,147 A 1,297 A 1,324 A 1,283 A 6,990 A ,170 E 1,340 E 1,366 E 1,309 E 5,185 E ,380 E Earnings Per Share Estimates (EPS is operating earnings before non-recurring items, but including employee stock options expenses) Q1 Q2 Q3 Q4 Year (Mar) (Jun) (Sep) (Dec) (Dec) 2013 $0.66 A $0.81 A $0.83 A $0.82 A $3.12 A 2014 $0.69 A $0.84 A $0.90 A $0.93 A $3.36 A 2015 $0.76 E $0.94 E $1.01 E $0.98 E $3.69 E 2016 $4.00 E Zacks Rank *: Short Term 1 3 months outlook 3 - Hold Projected EPS Growth - Next 5 Years % 9.0 * Definition / Disclosure on last page 2015 Zacks Investment Research, All Rights reserved North Canal Street, Chicago IL 60606

2 RECENT NEWS Lorillard's Fourth Quarter Earnings Beat Estimates on Cigarette Pricing Feb 11, 2015 Lorillard reported adjusted earnings of $0.93 per share in the fourth quarter of 2014, up 13.4% from the prior-year quarter. Higher cigarette sales and the impact of share repurchases in prior quarters led to earnings growth in the reported quarter. Earnings beat the Zacks Consensus Estimate of $0.92 by 1.1%. Net sales in the reported quarter grew 1.4% year over year to $1.768 billion due to an increase in net sales of cigarettes, partially offset by a decline in net sales of electronic cigarettes. Revenues comprehensively beat the Zacks Consensus Estimate of $1.285 billion by 37.6%. Gross profit improved 10.3% to $727 million in the quarter driven by higher margins in the cigarette segment. Adjusted operating income grew 12.8% to $590 million, driven by operating efficiencies at the cigarette segment. Full-Year Results In 2014, adjusted earnings of $3.36 per share lagged the Zacks Consensus Estimate by a cent, but increased 7.7% year over year. Net sales grew 0.6% year over year to $6.990 billion. Revenues comprehensively beat the Zacks Consensus Estimate of $5.051 billion by 38.4%. Segment Details Cigarettes: Despite lower cigarette unit sales volumes, the company managed to increase its cigarette sales by 2.4% year over year to $1.7 billion. The increase was driven by a 4.7% increase in average net cigarette selling prices. Total wholesale cigarette volumes declined 0.9% to 9.76 billion units in the fourth quarter including Puerto Rico and U.S. shipments. Excluding Puerto Rico and U.S. shipments, total wholesale cigarette volumes declined 1% to 9.65 billion in the quarter. We note that the cigarette volume decline rate was narrower than the sequential quarter, owing to an improving economy and lower fuel prices. In the reported quarter, Lorillard's domestic retail market share climbed 0.3 share point to 15.2%, backed by strong gains in the company's flagship brand Newport. Its domestic retail market share also increased 0.3 share point to 13.0%. Newport s market share was driven by continued strengthening of Newport Menthol in its core geographies, continued success in expansion markets and improved volumes after the launch of Newport Non-Menthol. Lorillard's domestic retail share of the menthol market increased 0.1 share point to 40.2% in the reported quarter. Adjusted gross profit increased 11% to $714 million, driven by higher cigarette sales. Adjusted operating profit increased 16% to $610 million, owing to higher gross profit and lower selling, general and administrative expenses. Electronic Cigarettes: Segment net sales during the fourth quarter declined 27.8% to $39 million. The decline was due to lower sales of blu ecigs in the U.S., reflecting a decrease in unit volume. Sales also declined due to greater competition from rivals Altria Group and Reynolds American, who recently rolled out their respective e-cigarettes brands MarkTen and Vuse nationwide, supported by aggressive introductory "free trial" and other promotional programs. Thankfully, the decline in segment sales was narrower than the prior quarter due to the launch of the new blu PLUS+ rechargeable kit nationwide during the fourth quarter. Equity Research LO Page 2

3 The company s brand blu (formerly known as Skycig, a leading premium brand of electronic cigarettes in the UK which was acquired in Oct 2013) generated only $2 million in sales in the fourth quarter. However, net sales are expected to increase significantly during 2015 as a result of continued marketing of blu and expanded retail distribution. During the fourth quarter, blu (U.K) entered into an agreement with Fontem Ventures B.V. ("Fontem"), Imperial Tobacco Group's electronic cigarette operating subsidiary. Per the deal, Fontem will act as the exclusive distributor of blu electronic cigarette products, including blu starter kits, disposable e-cigarettes, personal vaporizers and e-liquids in the United Kingdom. Adjusted gross profit declined significantly by 87.5% to $2 million in the fourth quarter due to lower segment sales. Adjusted operating loss was $20 million in the reported quarter compared with a loss of $3 million in the fourth quarter of This was due to higher selling, general and administrative costs and a decline in gross profit. Merger Update On Jul 15, Lorillard and peer Reynolds American entered into an agreement per which Reynolds agreed to take over Lorillard for $27.4 billion, including assumption of net debt. In connection with the transaction, Reynolds also announced that it has reached an agreement with Imperial Tobacco Group PLC, the fourth-largest international tobacco company. Per the agreement, Imperial agreed to purchase the Kool, Salem, Winston, Maverick and blu ecigs brands and other assets and liabilities from Reynolds and Lorillard for $7.1 billion in cash. The shareholders of both the companies approved the merger in Jan The companies now await the approval of the Federal Trade Commission. Lorillard is tethered to menthol cigarettes. It would be able to diversify with Reynolds American's traditional tobacco brands such as Camel and American Spirit, if the $27.4 billion Reynolds-Lorillard deal materializes. In addition, both companies are likely to see significant cost synergies and should be able to shed a great deal of overlapping costs. However, the combined entity might pose a threat to its peer Altria Group, which manufactures Marlboro cigarettes and commands more than 40% market share in the U.S. The companies expect the transactions to close in the first half of VALUATION Lorillard s current trailing 12-month earnings multiple is 20.1x, representing a premium of 6.3% to the industry average of 18.9x. Over the last five years, Lorillard s shares have traded in the range of 11.1x to 19.7x trailing 12-month earnings. Based on 2015 earnings estimate of $3.69, the stock is trading at 18.3x, a 28.2% discount to the industry average of 25.5x. Our target price of $71.00 is based on approximately 19.2x our 2015 earnings estimate. Lorillard holds a Zacks Rank #3 (Hold). Equity Research LO Page 3

4 Key Indicators F1 F2 Est. 5-Yr EPS Gr% P/CF 5-Yr High 5-Yr Low LORILLARD CO (LO) Industry Average S&P REYNOLDS AMER (RAI) ALTRIA GROUP (MO) UNIVL CORP -VA (UVV) ALLIANCE ONE (AOI) TTM is trailing 12 months; F1 is 2014 and F2 is 2015, CF is operating cash flow P/B Last Qtr. P/B 5-Yr High P/B 5-Yr Low ROE D/E Last Qtr. Div Yield Last Qtr. EV/EBITDA LORILLARD CO (LO) NA NA NA NA Industry Average S&P Equity Research LO Page 4

5 Earnings Surprise and Estimate Revision History NOTE THIS IS A NEWS-ONLY UPDATE; THE REST OF THIS REPORT HAS NOT BEEN UPDATED YET. Equity Research LO Page 5

6 OVERVIEW Founded in 1760, North Carolina-based Lorillard operates through two operating segments Cigarettes segment and the Electronic Cigarettes segment. the The Cigarettes segment consists principally of the operations of Lorillard, Inc., Lorillard Tobacco (a subsidiary of Lorillard, Inc.) and related subsidiaries. Lorillard Tobacco is the third largest manufacturer of cigarettes in the United States and produces cigarettes for both the premium and discount segments of the domestic cigarette market. Newport, its flagship menthol flavored premium cigarette brand, is the top selling menthol flavored cigarette and the second largest cigarette brand in the U.S, based on gross units sold in In addition to the Newport brand, the company s product line includes four other brands namely Kent, True, Maverick, and Old Gold. These five brands include 43 different product offerings, which vary in price, taste, flavor, length and packaging. The Electronic Cigarettes segment consists principally of the operations of LOEC, Inc. (a subsidiary of Lorillard, Inc), Cygnet U.K. Trading Ltd and related entities. LOEC, Inc. is a leading electronic cigarette company in the United States and markets its brand under blu ecig, which was acquired in Apr Cygnet, based in United Kingdom is also a subsidiary of Lorillard, Inc. and markets its e-cigarette under SKYCIG brand, which was acquired in Oct 2013 and is currently named as blu. All of the company s products are manufactured at its Greensboro, N.C. facility. On Jul 15, Lorillard and peer Reynolds American entered into an agreement per which Reynolds agreed to take over Lorillard for $27.4 billion, including assumption of net debt. In connection with the transaction, Reynolds also announced that it has reached an agreement with Imperial Tobacco Group to purchase the Kool, Salem, Winston, Maverick and blu e-cigs brands and other assets and liabilities from Reynolds and Lorillard for $7.1 billion in cash. The companies expect the transactions to close in the first half of REASONS TO BUY Growing Cigarette Market Share Owing to Strong Brands: Lorillard is the third largest manufacturer of cigarettes in the United States, focused on building brands and brand power. Newport, its flagship premium cigarette brand, is the top selling menthol and second largest selling cigarette brand overall in the U.S. based on gross units sold in Despite the slowdown in the tobacco industry, Lorillard has managed to consistently gain market share over the last 10 years. In the first half of 2014, its market share grew 30 basis points year over year to 15.1%, driven by continued strengthening of Newport Menthol in its core geographies, continued success in new markets and improved volumes after the launch of Newport Smooth Select and Newport Non-Menthol Gold in Newport has a strong domestic retail market share, which has been escalating since 2009, despite higher pricing. The company expects the brand to continue to gain market share in the coming quarters. Product Innovation Adding to Growth: Lorillard has launched many new products amid the declining tobacco industry in order to boost sales. In the cigarettes category, the company launched Newport Non-Menthol Gold cigarette in the fourth quarter of 2013 and then re-launched it in two test markets during the third quarter of Newport Smooth Select Menthol cigarettes, which were launched in the second quarter of 2013, have also been doing well. Equity Research LO Page 6

7 In the e-cigarette category, the company launched blu ecigs cherry disposable products in the third quarter of 2014, which led to a sequential increase in U.S. net sales for the brand. The momentum is expected to continue. Recently, the company also introduced enhanced rechargeable kits called blu PLUS+ Tanks nationwide for adult smokers. These kits are better than the original cartridges and come in variety of flavors. blu ecigs plans to roll out more flavors in The SKYCIG brand was named as blu (U.K.) and then re-branded as blu and launched at retail stores in UK and online during the second quarter of The retail exposure has been good so far and is expected to increase significantly during the fourth quarter of 2014 and 2015, which, along with continued marketing of blu, is expected to drive an increase in net sales. Potential Benefits from Merger with Reynolds: Lorillard is tethered to menthol cigarettes and would be given valuable diversification with Reynolds American's traditional tobacco brands, such as Camel and American Spirit, if the Reynolds-Lorillard deal materializes. In addition, both companies are likely to see significant cost synergies. Since they share virtually identical manufacturing and distribution processes, the combined entity should be able to shed a great deal of overlapping costs. This should boost earnings soon after the merger closes. Strong Pricing Actions: Lorillard has always remained afloat amid declining volumes in the cigarette industry with the help of increased pricing. Cigarette prices have been increasing since 1998 and these have been driven by increases in federal, state and local excise taxes and manufacturer costs. It is impressive that the company has been able to maintain stable market share despite repeated price increases in several markets. This shows that the company has a strong business model and brands. Moreover, the price hikes help Lorillard maintain margins at the desired level. Growing Demand for Cigarette Alternative: Increasing health consciousness among the youth has reduced the demand for tobacco over time, thus forcing the company to look for other alternatives like e-cigarettes. E-cigarettes look like traditional cigarettes but do not produce smoke, ash or smell. With the acquisition of the e-cigarette brand blu e-cigs in Apr 2012, the company expanded its footprint in the electronic cigarettes market. Lorillard took a step further to strengthen its e-cigarette business with the acquisition of SKYCIG (now branded as blu) in Oct, Though e-cigarette sales are facing a slowdown recently due to lower price of rechargeable kits as well as a decline in unit volume, the company still expects to make a series of technical advances in the blu brand in Returning Value to Shareholders: Lorillard is one of the most efficient and aggressive companies in the tobacco industry that regularly increases shareholder return in the form of dividends and share repurchases. In Jun 2014, the company completed its $1 billion share repurchase program that was announced in Mar 2013 and amended in May However, in connection with the merger agreement, Lorillard suspended its future share repurchases. The company has increased dividend payment every year since In Feb 2014, Lorillard's board approved a 12% increase in its quarterly dividend, significantly up from the last hike of 6.5%. The company has grown its quarterly dividends at an average annual growth rate of about 16% since Equity Research LO Page 7

8 REASONS TO SELL Slipping E-Cigarette Sales Due to Increased Competition: Lorillard has reported significant declines in its electronic cigarettes sales in the last two quarters, raising concerns and questions about the strength of the nascent market. blu ecig, when initially launched, had 47% share of the U.S. market. Sales of the e-cigarette segment declined 35% to $37 million in the second quarter. Its retail share fell 1.1 percentage point to 40.9%. The significant decline came from greater competition from rivals Altria Group Inc. and Reynolds American Inc., who rolled out their own e-cigarettes brands - Vuse and MarkTen nationwide. These were earlier available in only two states. Also, the shift in consumer preference from smaller e-cigarettes to tank devices, which are typically larger and have longer-lasting batteries and a puff that is more similar to a combustible cigarette are also harming e-cigarette sales. Declining Cigarette Volumes: Lorillard has witnessed a decline in cigarette volumes since the past many quarters. The slowdown in the tobacco industry, increasing health consciousness among consumers and significantly higher prices of cigarettes have hurt volumes. Increases in federal, state and local excise taxes and manufacturer price have increased cigarette prices, which have significantly impacted the consumption of cigarettes. In addition, a rise in the number of people who quit smoking has also impacted sales. The company has been making constant efforts to revive volumes and is also keen on new product launches and offering discounts. However, these are yet to contribute to volume growth. We believe that volumes are expected to decline further as regulations on traditional cigarettes tighten and consumers shift to alternate tobacco products. Prohibition on Advertisements of Tobacco Products: Tobacco companies cannot market their products through advertising. Advertising of tobacco products through television and radio has been prohibited since Under the State Settlement Agreements, Lorillard cannot use billboard advertising, cartoon characters, sponsorship of concerts, non-tobacco merchandise bearing Lorillard s brand names and various other advertising and marketing techniques. Further, Lorillard s Newport brand can advertise in a limited number of magazines that meet certain requirements regarding the age and composition of their readership. In fact, Newport is the company s only brand that receives magazine advertising support. Also, Lorillard does not sell cigarettes directly to its customers and does not ship products directly to retail stores. This gives a chance to its competitors Philip Morris USA Inc. and R.J. Reynolds Tobacco Company to capture the retail shelf space available for the tobacco brands. Regulatory Restrictions: The global cigarette-making industry continues to be in a flux as it deals with increased regulation on packaging (graphic warning labels) in some international markets, heightened FDA concerns about public health issues of menthol cigarettes, and the advent of the electronic cigarette. In Mar 2011, the FDA intervened and wanted to remove menthol cigarettes from the markets but did not take an immediate action. In Jul 2013, the FDA noted through a report that menthol cigarette smokers were less successful in quitting the habit than non-menthol smokers. The European Parliament has introduced a law banning the sale of menthol cigarettes from 2022, which has also increased pressure on the United States to act. New restrictions on menthol cigarette sales would be a negative for Lorillard as the company has significant exposure in the menthol market. Equity Research LO Page 8

9 After regular cigarettes, e-cigarettes have also come under FDA review. In Mar 2014, the European Parliament imposed stronger rules on e-cigarettes, per which e-cigarettes, with nicotine strength of more than 20 milligrams per milliliter would need authorization as a medicine. Later in Apr 2014, the FDA proposed to regulate e-cigarettes, cigars, pipe tobacco, hookahs (water pipes) and dissolvable tobacco products, owing to the growing popularity of e-cigarettes among youngsters. The proposed rules, if finalized, will limit sales to minors, ban free samples, and require companies to give detailing of ingredients and warning labels as well as seek federal approval to sell e- cigarettes. However, the FDA does not recommend a restriction on flavored products or online sales and advertising of e-cigarettes. DISCLOSURES & DEFINITIONS The analysts contributing to this report do not hold any shares of LO. The EPS and revenue forecasts are the Zacks Consensus estimates. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. Zacks certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report. Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Because of individual objectives, the report should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed herein are subject to change. This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. Zacks or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. Zacks uses the following rating system for the securities it covers. Outperform- Zacks expects that the subject company will outperform the broader U.S. equity market over the next six to twelve months. Neutral- Zacks expects that the company will perform in line with the broader U.S. equity market over the next six to twelve months. Underperform- Zacks expects the company will under perform the broader U.S. Equity market over the next six to twelve months. The current distribution of Zacks Ratings is as follows on the 1019 companies covered: Outperform %, Neutral %, Underperform 6.3%. Data is as of midnight on the business day immediately prior to this publication. Our recommendation for each stock is closely linked to the Zacks Rank, which results from a proprietary quantitative model using trends in earnings estimate revisions. This model is proven most effective for judging the timeliness of a stock over the next 1 to 3 months. The model assigns each stock a rank from 1 through 5. Zacks Rank 1 = Strong Buy. Zacks Rank 2 = Buy. Zacks Rank 3 = Hold. Zacks Rank 4 = Sell. Zacks Rank 5 = Strong Sell. We also provide a Zacks Industry Rank for each company which provides an idea of the near-term attractiveness of a company s industry group. We have 264 industry groups in total. Thus, the Zacks Industry Rank is a number between 1 and 264. In terms of investment attractiveness, the higher the rank the better. Historically, the top half of the industries has outperformed the general market. In determining Risk Level, we rely on a proprietary quantitative model that divides the entire universe of stocks into five groups, based on each stock s historical price volatility. The first group has stocks with the lowest values and are deemed Low Risk, while the 5 th group has the highest values and are designated High Risk. Designations of Below-Average Risk, Average Risk, and Above-Average Risk correspond to the second, third, and fourth groups of stocks, respectively. Research Analyst Copy Editor Content Ed. QCA Lead Analyst Reason for Update Sneha Nahata Debasmita Banerjee Kinjel Shah Kinjel Shah Sneha Nahata 4Q14 Note Equity Research LO Page 9

Altria Group Inc (MO-NYSE)

Altria Group Inc (MO-NYSE) March 20, 2015 Altria Group Inc (MO-NYSE) Current Recommendation SUMMARY DATA NEUTRAL Prior Recommendation Underperform Date of Last Change 08/12/2009 Current Price (03/19/15) $51.27 Target Price $54.00

More information

Corcept Therapeutics, Inc.

Corcept Therapeutics, Inc. March 20, 2015 Corcept Therapeutics, Inc. NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/20/2015 Current Price (03/19/15) $5.85 Target Price $6.25 (CORT-NASDAQ) SUMMARY

More information

Orexigen Therapeutics, Inc.

Orexigen Therapeutics, Inc. February 27, 2015 Orexigen Therapeutics, Inc. Current Recommendation NEUTRAL Prior Recommendation Outperform Date of Last Change 06/06/2012 Current Price (02/26/15) $5.87 Target Price $6.25 SUMMARY DATA

More information

Perrigo Company plc (PRGO-NYSE)

Perrigo Company plc (PRGO-NYSE) March 20, 2015 Perrigo Company plc (PRGO-NYSE) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 09/02/2012 Current Price (03/19/15) $170.37 Target Price $179.00 SUMMARY

More information

Medivation, Inc. (MDVN-NASDAQ)

Medivation, Inc. (MDVN-NASDAQ) March 19, 2015 Medivation, Inc. (MDVN-NASDAQ) NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 03/25/2014 Current Price (03/18/15) $132.19 Target Price $139.00 SUMMARY

More information

Novo-Nordisk As (NVO-NYSE) Analyst Note

Novo-Nordisk As (NVO-NYSE) Analyst Note February 03, 2015 Novo-Nordisk As (NVO-NYSE) Analyst Note NEUTRAL Current Recommendation Prior Recommendation Outperform Date of Last Change 02/10/2014 Current Price (02/02/15) $44.73 Target Price $47.00

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive Data in Colon/Lung Cancers. Anticipating Initial Launch This Year OUTLOOK Small-Cap Research February 2, 2016 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-NYSE) VNRX: More Positive

More information

Global E-Cigarette Market- Industry Analysis & Outlook ( )

Global E-Cigarette Market- Industry Analysis & Outlook ( ) Global E-Cigarette Market- Industry Analysis & Outlook (2016-2020) ----------------------------------------- Executive Summary Electronic cigarettes, also known as E-cigarettes, electronic nicotine delivery

More information

Zacks Small-Cap Research

Zacks Small-Cap Research Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,

More information

Altria Group Inc. Ticker: MO

Altria Group Inc. Ticker: MO Altria Group Inc. Ticker: MO Business Description Altria Group Inc. through its subsidiaries manufactures and sells cigarettes, other tobacco products, machine-made large cigars and pipe tobacco. It also

More information

Reynolds American to Acquire Lorillard

Reynolds American to Acquire Lorillard Reynolds American to Acquire Lorillard The Next Step in Transforming Tobacco July 15, 2014 Forward Looking Statements This presentation contains forward-looking information. Future results or events can

More information

Vontobel Viewpoints FDA New Direction on Tobacco Our Take

Vontobel Viewpoints FDA New Direction on Tobacco Our Take Quality Growth Boutique TM Vontobel Viewpoints On July 28, 2017, the new Commissioner of the U.S. Food and Drug Administration (FDA), Scott Gottlieb, surprised the markets by launching a consultation paper

More information

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders

RAI reports strong 2Q16 performance and positive outlook; Accelerates returns to shareholders Contact: Investor Relations: Bob Bannon (336) 741-3359 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2016-22 RAI reports strong 2Q16 performance

More information

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance

RAI: Strong key-brands performance delivers 2Q13 profit growth; Company reaffirms full-year EPS guidance Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-10 RAI: Strong key-brands performance

More information

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK

Small-Cap Research. VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set Supports Earlier Findings of High Accuracy in Colon Cancer Detection OUTLOOK Small-Cap Research September 12, 2014 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Ste 1600, Chicago, IL 60606 VolitionRx Ltd (VNRX-OTC) VNRX: 938-Sample Set

More information

Q Investor Kit JANUARY-JUNE 2013

Q Investor Kit JANUARY-JUNE 2013 Q2 2013 Investor Kit JANUARY-JUNE 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK

Small-Cap Research. Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final Guidance for Phase 3 Protocol for TSC in Inoperable GBM OUTLOOK Small-Cap Research November 16, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Diffusion Pharmaceuticals Inc. (DFFN-NASDAQ) DFFN: FDA Gives Final

More information

Q Investor Kit JANUARY-MARCH 2013

Q Investor Kit JANUARY-MARCH 2013 Q1 2013 Investor Kit JANUARY-MARCH 2013 1 Swedish Match reporting segments Snus and snuff - Swedish snus (Scandinavia and US) - Moist snuff (US) - SMPM International Other tobacco products - Cigars (US)

More information

Q Investor Kit JANUARY-MARCH 2014

Q Investor Kit JANUARY-MARCH 2014 Q1 2014 Investor Kit JANUARY-MARCH 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

Q Investor Kit January December 2014

Q Investor Kit January December 2014 Q4 2014 Investor Kit January December 2014 Highlights for Q4 Sales up for all product areas and operating profit from product areas up by 8% Scandinavian hoarding for snus prior to tax increase in January

More information

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Melodie Tilson, Director of Policy

Melodie Tilson, Director of Policy Melodie Tilson, Director of Policy Non-Smokers Rights Association/ Smoking and Health Action Foundation PTCC Knowledge Exchange 18 June 2014 Disposable Rechargeable with pre-filled cartridges Rechargeable

More information

Small-Cap Research. Celator Pharma (CPXX-NASDAQ)

Small-Cap Research. Celator Pharma (CPXX-NASDAQ) Small-Cap Research June 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Celator Pharma (CPXX-NASDAQ) CPXX: Positive top line data reported for

More information

Q Investor Kit JANUARY-JUNE 2014

Q Investor Kit JANUARY-JUNE 2014 Q2 2014 Investor Kit JANUARY-JUNE 2014 Swedish Match reporting segments Snus and moist snuff Snus (Scandinavia and US) Moist snuff (US) SMPM International Other tobacco products Cigars (US) Chewing tobacco

More information

22nd Century Group, Inc. (XXII - $ Buy)

22nd Century Group, Inc. (XXII - $ Buy) Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs

Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion

More information

RESPONSE FROM ALTRIA:

RESPONSE FROM ALTRIA: RESPONSE FROM ALTRIA: FDA Regulation of Tobacco http://www.altria.com/en/cms/about_altria/federal_regulation_of_tobacco/default.aspx?src=top_nav http://www.fda.gov/tobaccoproducts/default.htm The Food

More information

SWEDISH MATCH RESULTS PRESENTATION Q3 2017

SWEDISH MATCH RESULTS PRESENTATION Q3 2017 SWEDISH MATCH RESULTS PRESENTATION Q3 2017 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

Q2 INVESTOR KIT JANUARY-JUNE 2011

Q2 INVESTOR KIT JANUARY-JUNE 2011 Q2 INVESTOR KIT JANUARY-JUNE 2011 Swedish Match reporting segments Reporting segments following the transaction with STG on October 1, 2010 Snus and snuff - Swedish snus in Scandinavia and US - US moist

More information

Small-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK

Small-Cap Research. Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report OUTLOOK Small-Cap Research May 25, 2017 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-NASDAQ) DMPI: Zacks Company Report DMPI: A New Phase

More information

RAI increases 3Q13 earnings on strong operating performance; tightens full-year EPS guidance

RAI increases 3Q13 earnings on strong operating performance; tightens full-year EPS guidance Contact: Investor Relations: Morris Moore (336) 741-3116 Media: Jane Seccombe (336) 741-5068 Reynolds American Inc. P.O. Box 2990 Winston-Salem, NC 27102-2990 RAI 2013-13 RAI increases 3Q13 earnings on

More information

Small-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK

Small-Cap Research. Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report OUTLOOK Small-Cap Research April 21, 2017 Grant Zeng, CFA 312-265-9421 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Oramed Pharmaceuticals (ORMP-NASDAQ) ORMP: Zacks Company Report ORMP:

More information

Old tobacco playbook gets new use by e- cigarettes 3 August 2013, by Michael Felberbaum

Old tobacco playbook gets new use by e- cigarettes 3 August 2013, by Michael Felberbaum Old tobacco playbook gets new use by e- cigarettes 3 August 2013, by Michael Felberbaum This undated image provided by Resound Marketing shows a screen grab of the new Blu Ecigs advertisement featuring

More information

Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market. David T. Levy Georgetown University

Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market. David T. Levy Georgetown University Competition in the Vaporized Nicotine Market and its Potential Impact on the Cigarette Market David T. Levy Georgetown University The E-Cigarette Summit: Science, Regulation and Public Health Washington,

More information

Q Investor Kit January December 2015

Q Investor Kit January December 2015 Q4 2015 Investor Kit January December 2015 Summary and Overview 2 Q4 and full year 2015: Headline numbers Sales for the full year increased by 9 percent and for the fourth quarter by 5 percent. In local

More information

Small-Cap Research. Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary Endpoint But Data-Within-Data Warrants Optimism OUTLOOK SUMMARY DATA

Small-Cap Research. Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary Endpoint But Data-Within-Data Warrants Optimism OUTLOOK SUMMARY DATA Small-Cap Research March 27, 2017 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Aevi Genomic Medicine (GNMX-NASDAQ) GNMX: SAGA Misses Primary

More information

2014 CAGNY Investor Presentation. February 19, 2014

2014 CAGNY Investor Presentation. February 19, 2014 2014 CAGNY Investor Presentation February 19, 2014 Management Team Participants Howard Willard EVP and Chief Financial Officer, Altria Group, Inc. Dave Beran President and Chief Operating Officer, Altria

More information

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, András Tövisi Chairman of the Board of Directors Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 25, 2014 András Tövisi Chairman of the Board of Directors Philip Morris ČR a.s. Annual General Meeting of Shareholders 2014

More information

Small-Cap Research. Delmar Pharma (DMPI-OTCQB)

Small-Cap Research. Delmar Pharma (DMPI-OTCQB) Small-Cap Research February 24, 2015 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Delmar Pharma (DMPI-OTCQB) DMPI: Ready to advance VAL-083 to pivotal

More information

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES Small-Cap Research August 26, 2016 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Uplist to Nasdaq

More information

Small-Cap Research. Auspex Pharmaceuticals Inc. Buy Prior Recommendation. Current Recommendation. N/A Date of Last Change 11/11/2014

Small-Cap Research. Auspex Pharmaceuticals Inc. Buy Prior Recommendation. Current Recommendation. N/A Date of Last Change 11/11/2014 Small-Cap Research December 17, 2014 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 Auspex Pharmaceuticals Inc. ASPX SD-809 Hits

More information

(GALE-NASDAQ) OUTLOOK

(GALE-NASDAQ) OUTLOOK Small-Cap Research November 7, 2013 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Galena Biopharma Inc. Galena: Reported sales from Abstral ahead

More information

Summary of Results for the First Half of FY2015/3

Summary of Results for the First Half of FY2015/3 Summary of Results for the First Half of FY2015/3 November 10, 2014 Tokyu Corporation (9005) http://www.tokyu.co.jp/ Contents Ⅰ.Executive Summary 2 Ⅱ.Conditions in Each Business 5 Ⅲ.Details of Financial

More information

Imperial Brands Maximising Category Opportunities CAGNY February 2019

Imperial Brands Maximising Category Opportunities CAGNY February 2019 Imperial Brands Maximising Category Opportunities CAGNY 2019 21 February 2019 Disclaimer Certain statements in this announcement constitute or may constitute forward-looking statements. Any statement in

More information

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products

Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Products Effective and Compliance Dates Applicable to Retailers, Manufacturers, Importers, and Distributors of Newly Deemed Tobacco Quick Facts Retailers that mix and prepare e-liquids or create or modify vaporizers

More information

APPENDIX A: Tobacco Marketing Expenditure Categories

APPENDIX A: Tobacco Marketing Expenditure Categories APPENDIX A: Tobacco Marketing Expenditure Categories The Federal Trade Commission (FTC) issues reports on annual cigarette and smokeless tobacco marketing expenditures, which are based on data from the

More information

How to Regulate E-Cigarettes? Are we asking the right questions?

How to Regulate E-Cigarettes? Are we asking the right questions? How to Regulate E-Cigarettes? Are we asking the right questions? Eric N. Lindblom Director, Tobacco Control and Food & Drug Law O Neill Institute for National & Global Health Law Georgetown University

More information

JT Group Consolidated Financial Results 2018 First Quarter Results

JT Group Consolidated Financial Results 2018 First Quarter Results JT Group Consolidated Financial Results 2018 First Quarter Results Naohiro Minami JT Group Chief Financial Officer *Please be reminded that the figures shown on these slides may differ from those shown

More information

Nielsen: Tobacco 'All Channel' Data 1/27

Nielsen: Tobacco 'All Channel' Data 1/27 February 6, 2018 : Tobacco 'All Channel' Data 1/27 Marlboro Volume & Share Pressures Continue Tobacco Cig Industry Pricing Continues to Offset Vol Weakness As Headwind from CA $2/pk Cig Excise Tax Continues

More information

Electronic Nicotine and Non Nicotine Delivery Systems (ENDS)

Electronic Nicotine and Non Nicotine Delivery Systems (ENDS) Electronic Nicotine and Non Nicotine Delivery Systems (ENDS) Dr Meena Dawar Medical Health Officer 30 September 2014 1 VCH MHO Recommendations 1. Include e-cigarettes and related ENDS devices in the City

More information

TFI WHO 20 Avenue Appia 1211 Geneva 27, Switzerland. Gentlemen:

TFI WHO 20 Avenue Appia 1211 Geneva 27, Switzerland. Gentlemen: Donald D. Foreman, Director Federal Government Affairs 1455 Pennsylvania Avenue, NW, Suite 925 Washington, DC 20004 Telephone: (202) 626-7200 Fax: (202) 626-7208 TFI WHO 20 Avenue Appia 1211 Geneva 27,

More information

SWEDISH MATCH RESULTS PRESENTATION Q4 2018

SWEDISH MATCH RESULTS PRESENTATION Q4 2018 SWEDISH MATCH RESULTS PRESENTATION Q4 2018 DISCLAIMER The information contained in this presentation has not been independently verified and is subject to change without notice and neither Swedish Match,

More information

Global E-Cigarette & Vaporizer Market Research Report - Forecast to 2027

Global E-Cigarette & Vaporizer Market Research Report - Forecast to 2027 Report Information More information from: https://www.marketresearchfuture.com/reports/788 Global E-Cigarette & Vaporizer Market Research Report - Forecast to 2027 Report / Search Code: MRFR/CR/0304-CRR

More information

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES

scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL (MBVX - Nasdaq) OUTLOOK ZACKS ESTIMATES Small-Cap Research February 24, 2017 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Suite 1600, Chicago, IL 60606 MabVax Therapeutics Holdings, Inc. MBVX: Update on

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

Walgreens (WAG) Analyst: Juan Fabres Fall 2014

Walgreens (WAG) Analyst: Juan Fabres Fall 2014 Recommendation: Buy Target Price August 31, 2016: $77.57 1. Reasons for the Recommendation With the acquisition of Alliance Boots in Europe, Walgreens will be the first US pharmacy to operate retail stores

More information

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region

Investor Day LA&C Region Lausanne, September 29, Jeanne Pollès President, Latin America & Canada Region Investor Day LA&C Region Lausanne, September 29, 2016 Jeanne Pollès President, Latin America & Canada Region Agenda Regional Overview and Performance Regional Strategies Key Markets Conclusion 2 LA&C Regional

More information

The Cigarette Market in Netherlands

The Cigarette Market in Netherlands The Cigarette Market in Netherlands Product Code: CG0148MR Published Date: April 2015 Report Price: US$ 975 (Single Copy) Synopsis Cigarettes in Austria report is a qualitative report providing extensive

More information

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007

JT Reports Consolidated Financial Results For the Nine-Month Period that Ended December 31, 2007 Contact: Yukiko Seto General Manager Media and Investor Relations Division Japan Tobacco Inc. Tokyo: +81-3-5572-4292 FOR IMMEDIATE RELEASE JT Reports Consolidated Financial Results For the Nine-Month Period

More information

Business Update. Reynolds American Inc. May 16, 2016

Business Update. Reynolds American Inc. May 16, 2016 Business Update Reynolds American Inc. May 16, 2016 1 Agenda Overview Susan Cameron President and Chief Executive Officer, RAI Operating companies business and brand highlights Debra Crew President and

More information

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free

Investor Day EEMA Region Lausanne, September 29, Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Investor Day EEMA Region Lausanne, September 29, 2016 Drago Azinovic President, Eastern Europe, Middle East & Africa Region & PMI Duty Free Agenda Overview and Key Results Vision and Strategic Pillars

More information

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018

Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018 Annual General Meeting of Shareholders of Philip Morris ČR a.s. Kutná Hora April 27, 2018 Árpád Könye Chairman of the Board of Directors Total Cigarette Market Czech Republic Total cigarette market down

More information

FY2016 1H Results. Cookpad Inc.

FY2016 1H Results. Cookpad Inc. FY2016 1H Results Cookpad Inc. 1 1H Highlights Premium Service -Premium Service revenue increased by 39.6% YoY. -Number of premium members grew by 12.0% YoY to exceed 1.85 million. Advertising -Advertising

More information

Category ADVICE. For Tobacconists Only.

Category ADVICE. For Tobacconists Only. 2018 For Tobacconists Only www.bestway.co.uk www.batleys.co.uk MARKET INSIGHT Availability of best selling brands is absolutely critical 1 in 4 adult smokers would leave the store without making a purchase

More information

Results Briefing. 15 ~ 17 May 2007

Results Briefing. 15 ~ 17 May 2007 Results Briefing 1Q Q & 3 Months ended 31 Mar. 2007 15 ~ 17 May 2007 Content Key highlights Financial Corporate Financial results Industry overview Q&A Appendix 2 2 Key Highlights for the Period Key Highlights

More information

SWEDISH MATCH INVESTOR KIT Q4 2016

SWEDISH MATCH INVESTOR KIT Q4 2016 SWEDISH MATCH INVESTOR KIT Q4 2016 A look at the quarter 2 Q4 HEADLINE BULLETS Sales increased by 6 percent to 3,957 MSEK (3,719) for the fourth quarter and by 7 percent to 15,551 MSEK (14,486) for the

More information

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM

DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf

More information

Nielsen: Tobacco 'All Channel' Data 4/21

Nielsen: Tobacco 'All Channel' Data 4/21 May 1, 2018 : Tobacco 'All Channel' Data 4/21 Marlboro N.T. Headwinds Prevail Tobacco Cig Ind Vol Decelerates Cig industry vols declined -4. in the 4- wk period ended 4/21/18 (vs -4.4% for 12-wks), a deceleration

More information

Research Study: Court-Ordered Corrections of Tobacco Industry Racketeering PRELIMINARY REPORT Background Methods Results Conclusions

Research Study: Court-Ordered Corrections of Tobacco Industry Racketeering PRELIMINARY REPORT Background Methods Results Conclusions Research Study: Court-Ordered Corrections of Tobacco Industry Racketeering National Poll Shows Support for Policies, Lawmakers Rejection of Tobacco Industry Influences PRELIMINARY REPORT Background Internal

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

E-Cigs, Etc.: Policy Options for Regulating Nicotine Delivery Devices. Indiana Local Boards of Health Webinar Feb. 12, 2015

E-Cigs, Etc.: Policy Options for Regulating Nicotine Delivery Devices. Indiana Local Boards of Health Webinar Feb. 12, 2015 E-Cigs, Etc.: Policy Options for Regulating Nicotine Delivery Devices Indiana Local Boards of Health Webinar Feb. 12, 2015 How to Use Webex If you can hear us through your computer, you do not need to

More information

Telekom Austria Group Results for the 1st Quarter May 27, 2003

Telekom Austria Group Results for the 1st Quarter May 27, 2003 Telekom Austria Group Results for the 1st Quarter 2003 May 27, 2003 1 Cautionary Statement This presentation contains certain forward-looking statements. Actual results may differ materially from those

More information

The Economics of Smoking

The Economics of Smoking The Economics of Smoking One of the potential problems (from an economic perspective) with smoking is that there may be an externality in consumption, so there may be difference between the private and

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

MARKETING STANDARDS FOR MEMBERSHIP

MARKETING STANDARDS FOR MEMBERSHIP MARKETING STANDARDS FOR MEMBERSHIP The Vapor Technology Association (VTA) is a leading national trade association in the electronic cigarette and vapor product industry. VTA represents the manufacturers,

More information

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011

Hyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011 Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai

More information

Investor Day Lausanne, September 27, 2018

Investor Day Lausanne, September 27, 2018 Investor Day Lausanne, September 27, 2018 Jacek Olczak Chief Operating Officer OPERATING AROUND THE ADULT CONSUMER 2 Operating Around the Adult Consumer CC RRPs PMI Combustible Cigarette Performance Reduced-Risk

More information

ESPs are battery-operated devices that contain cartridges filled with liquid chemicals. The chemicals turn into a vapour that the user inhales (this

ESPs are battery-operated devices that contain cartridges filled with liquid chemicals. The chemicals turn into a vapour that the user inhales (this ESPs are battery-operated devices that contain cartridges filled with liquid chemicals. The chemicals turn into a vapour that the user inhales (this is called vaping). They do not contain tobacco. They

More information

Public Health Policy Change Series

Public Health Policy Change Series Public Health Policy Change Series BEYOND CIGARETTES: FEDERAL REGULATION OF OTHER TOBACCO PRODUCTS Public Health Policy Change Webinar Series Providing substantive public health policy knowledge, competencies

More information

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1-

BANK HANDLOWY W WARSZAWIE S.A. 1Q 2009 consolidated financial results -1- BANK HANDLOWY W WARSZAWIE S.A. 1Q 29 consolidated financial results -1- Macroeconomic situation in 1Q 29 Deep drop in industrial output in January and February, albeit business confidence indicators suggest

More information

Zacks Small-Cap Research Sponsored Impartial - Comprehensive

Zacks Small-Cap Research Sponsored Impartial - Comprehensive Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 27, 2018 Grant Zeng, CFA 312-265-9466 gzeng@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Atossa Genetics (ATOS-NASDAQ)

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

TOBACCO TAXATION, TOBACCO CONTROL POLICY, AND TOBACCO USE

TOBACCO TAXATION, TOBACCO CONTROL POLICY, AND TOBACCO USE TOBACCO TAXATION, TOBACCO CONTROL POLICY, AND TOBACCO USE Frank J. Chaloupka Director, ImpacTeen, University of Illinois at Chicago www.uic.edu/~fjc www.impacteen.org The Fact is, Raising Tobacco Prices

More information

scr.zacks.com 111 North Canal Street, Chicago, IL (DEPO-NASDAQ) UPDATE ZACKS ESTIMATES

scr.zacks.com 111 North Canal Street, Chicago, IL (DEPO-NASDAQ) UPDATE ZACKS ESTIMATES Small-Cap Research December 19, 2013 Jason Napodano, CFA 312-265-9421 jnapodano@zacks.com scr.zacks.com 111 North Canal Street, Chicago, IL 60606 Depomed Inc. (DEPO-NASDAQ) DEPO: Another Fine Deal For

More information

Designing a Smoke-Free Future

Designing a Smoke-Free Future Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and

More information

Investor Day EU Region Lausanne, June 26, Drago Azinovic President, European Union Region Philip Morris International

Investor Day EU Region Lausanne, June 26, Drago Azinovic President, European Union Region Philip Morris International Investor Day EU Region Lausanne, June 26, 2014 Drago Azinovic President, European Union Region Philip Morris International Agenda Strong Business Fundamentals Strategies for Growth Key Markets Concluding

More information

Raze-On. Tobacco 101

Raze-On. Tobacco 101 Raze-On Tobacco 101 Key Messages Most people don t use tobacco Tobacco kills Nicotine is addictive The tobacco industry targets youth Tobacco Use in Teens 80% of adult smokers start before the age of 18

More information

The Latest on Vaping Among U.S. Teens

The Latest on Vaping Among U.S. Teens The Latest on Vaping Among U.S. Teens Jon Macy, PhD, MPH Indiana University School of Public Health Bloomington Presentation Outline Overview of Electronic Nicotine Delivery Systems (ENDS) New Prevalence

More information

Forward Looking Information

Forward Looking Information Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned

More information

SNUS ON THE LOOSE: Big Tobacco s s latest attempt to make nicotine more attractive

SNUS ON THE LOOSE: Big Tobacco s s latest attempt to make nicotine more attractive SNUS ON THE LOOSE: Big Tobacco s s latest attempt to make nicotine more attractive U.S. Smokeless Tobacco Market Historically the preserve of smaller, specialized companies: Conwood U.S. U.S. Smokeless

More information

SUMMARY. Risk Level * ,214 A ,583 A ,674 E ,710 E

SUMMARY. Risk Level * ,214 A ,583 A ,674 E ,710 E February 6, 2015 Roche Holding AG Current Recommendation Prior Recommendation Neutral Date of Last Change 02/06/2015 Current Price (02/05/15) $33.81 Target Price $31.00 UNDERPERFORM SUMMARY (RHHBY-OTC)

More information

GENERAL INFORMATION AND INSTRUCTIONS

GENERAL INFORMATION AND INSTRUCTIONS NON-PARTICIPATING MANUFACTURER CERTIFICATION FOR LISTING ON OREGON DIRECTORY GENERAL INFORMATION AND INSTRUCTIONS Who is required to file this Certification? Any tobacco product manufacturer who is a non-participating

More information

JTI Switzerland. JTI Schweiz 3

JTI Switzerland. JTI Schweiz 3 JTI Schweiz 3 Who we are 300 employees JTI has been manufacturing tobacco products in the Wiggertal area for over 45 years. The local market organization and the production facility in Dagmersellen (canton

More information

METVIX PDT ON THE MARKET IN GERMANY AND UK

METVIX PDT ON THE MARKET IN GERMANY AND UK METVIX PDT ON THE MARKET IN GERMANY AND UK PhotoCure ASA First Quarter Report 2003 Highlights: The launches of Metvix PDT by Galderma in February in Germany and in May in the UK, have triggered milestone

More information

The Cigarette Market in Greece

The Cigarette Market in Greece The Cigarette Market in Greece Product Code: CG0145MR Published Date: April 2015 Report Price: US$ 975 (Single Copy) Synopsis Cigarettes in Greece report is a qualitative report providing extensive and

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical

Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

OUTLOOK FOR U.S. TOBACCO. Tom Capehart Agricultural Economist Economic Research Service U.S. Department of Agriculture

OUTLOOK FOR U.S. TOBACCO. Tom Capehart Agricultural Economist Economic Research Service U.S. Department of Agriculture Outlook 98 For Release: Tuesday February 24, 1998 OUTLOOK FOR U.S. TOBACCO Tom Capehart Agricultural Economist Economic Research Service U.S. Department of Agriculture The outlook for U.S.-grown tobacco

More information